Biomedical Research and Therapy Logo

Biomedical Research and Therapy

Review Open Access Logo

Vitamin D and COVID-19: A Physiological Perspective

Pendhamma Sindhusen 1, * ORCID logo

  1. Pathumwan Demonstration School, Thailand
Correspondence to: Pendhamma Sindhusen, Pathumwan Demonstration School, Thailand. ORCID: https://orcid.org/0000-0002-5310-436X. Email: [email protected].
Volume & Issue: Vol. 8 No. 5 (2021) | Page No.: 4358-4366 | DOI: 10.15419/bmrat.v8i5.674
Published: 2021-05-31

Online metrics

Statistics from the website

  • HTML Views: 9786
  • PDF Views: 2010
  • XML Views: 0

Statistics from Dimensions

Statistics from PlumX
Copyright © 2021 by the author(s).

This article is published with open access by BioMedPress. This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. 

Abstract

Known for its ability to enhance the performance of the immune system, preclude microbial infections, and reduce susceptibility to influenza, Vitamin D (or 1,25-dihydroxyvitamin D (1,25(OH)2D) as the active form) has garnered a positive reputation in the management of COVID-19 for some time. Its deficiency is statistically correlated with infection of the disease, as well as disease severity and fatalities. There have been suggestions that Vitamin D supplements could either prevent the contraction of SARS-CoV-2, the coronavirus which causes the disease or alleviate the symptoms of the disease. Indeed, data have established a relationship between Vitamin D supplementation and the severity of respiratory illnesses, with some assays indicating optimistic results in COVID-19 patients who were supplemented with the vitamin. Accordingly, a great deal of research and efforts have been put into investigating the physiological mechanisms in the human body attributable to the vitamin’s reputation against the coronavirus. Combined with what was already discovered before the advent of SARS-CoV-2, a great amount of knowledge has consequently now been unveiled. Via regulation of various pathways, 1,25(OH)2D promotes the production of antimicrobial peptides, autophagy, as well as integrity and impermeability of cellular junctions against pathogens. Moreover, it mitigates the consequences of SARS-CoV-2 infection, such as cytokine storm (through immunomodulation of T cell differentiation pathways) and lung injury (through stimulation of the Angiotensin-Converting Enzyme 2 (ACE2) and manipulation of the Renin-Angiotensin System (RAS)). Nevertheless, Vitamin D deficiency still plagues the global population across all age groups, possibly contributing to the heightened global exposure to the coronavirus. With the COVID-19 pandemic inexorably raging on with no prospect of termination observable in the foreseeable future, this review article provides a concise yet thorough insight into the vast knowledge which could illuminate the significance of Vitamin D amidst the current predicament experienced by mankind, as well as instigate further curiosity and ignite further investigations into the role of vitamins, such as Vitamin D, as a safeguard against SARS-CoV-2.

Keywords: 1,25-dihydroxyvitamin D Angiotensin Converting Enzyme 2 COVID-19 Renin-Angiotensin System SARS-CoV-2 T-cell Differentiation Vitamin D

Background

The outbreak of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which causes the Coronavirus Disease 2019 (COVID-19), has engendered a global pandemic placing a great toll upon humanity1. Consequently, there has been an astronomical amount of interest in any available means to alleviate such a toll on science and medical communities. One of those means happens to be the use of Vitamin D.

Known otherwise as Calcitriol or 1,25-dihydroxycholecalciferol, Vitamin D is a steroid hormone derived from dietary intake or endogenous synthesis, conditional upon exposure to sunlight ultraviolet radiation2. Past studies have established it as an integral agent in the functioning of the human immune system with the roles of immunomodulation and promotion of antimicrobial peptide expression3, 4, 5, 6, 7, 8. Data have also indicated a link between its insufficiency or deficiency and vulnerability to infections, especially in the respiratory tract9, 10, 11. For this reason, intense research has been undertaken to shed light on the relevance of Vitamin D amidst the ongoing COVID-19 pandemic and to investigate the possible benefits of its supplementation. The results were promising; both statistical and clinical studies discovered a correlation between low vitamin D levels and increased COVID-19 risk, as well as infection severity and mortality12, 13, 14, 15, 16, 17. In conjunction with knowledge from past research, a notion has been developed that the correlation is due to the vitamin’s promotive role in the secretion of such antimicrobial peptides as β-defensin 2 (BD2) and cathelicidins, which not only act to eradicate microbes themselves but also help in the recruitment of cells in the human innate immune system, the autophagy of virus-borne cells, and the maintenance of cellular junctions, all of which are believed to help eradicate SARS-CoV-2 from the bodies of the afflicted2. The vitamin’s anti-inflammatory property is also accredited to suppressing the adaptive immune system’s overaction that could entail a cytokine storm, which is accountable for symptoms, deterioration, and eventual fatality in multifarious cases15.

Throughout this review article, the roles and mechanisms of Vitamin D are assiduously examined, using available data from apposite studies conducted hitherto that converged to provide a basis for the article's summarization. With vitamin D deficiency remaining a pre-eminent medical condition extensively affecting a sizeable portion of the global population18, the ultimate purpose is to highlight the significance of the steroidal vitamin. The use of vitamin D has heightened in the wake of the Coronavirus outbreak and reminds the science and medical communities, as well as the general populace, of its potential efficacy in this grueling pandemic.

Vitamin D and the Immune System

Apart from its functions in calcium homeostasis and the maintenance of the skeletal system, vitamin D has played a critical role in the human immune system. Receptors for its active form, 1,25-dihydroxyvitamin D (1,25(OH)D), have been found in cells of the immune system, including B cells, T cells, and such antigen-presenting cells (APCs) as macrophages and dendritic cells, which have the 1α-hydroxylase enzyme (CYP27B1) that synthesizes Vitamin D from its precursor, 25-hydroxyvitamin D (25-OHD)3, 1. Strikingly, such a synthesis is entirely independent of regulation by the Parathyroid Hormone (PTH), inducible by cytokines, and ultimately regulated by the abundance of 25-OHD, which makes the CYP27B1 of immune cells exclusively dissimilar to its renal counterpart. The availability of the receptors (Vitamin D Receptors; VDR) and CYP27B1 in cells of the immune system allows them to generate active Vitamin D autonomously and to utilize it instantaneously. Such a provision suggests an autocrine activity of Vitamin D in the immunological sphere and its overall role in the body’s defense mechanisms. Moreover, CYP27B1 has also been found in epithelial cells, which constitutes the first line of defense and plays a crucial role in mediating local immune responses, including instigating inflammation and recruiting immune cells via cytokine and chemokine molecules19. Accordingly, a conceptualization about the immunological functions of the steroidal hormones has taken root, which has helped to explicate the correlation between low serum 25-OHD levels and proneness to infections, as demonstrated by multiple studies in the past20, 21, 22, 23, 24, 25.

Role of Vitamin D in Antiviral Mechanisms

As mentioned previously, the coexistence of CYP27B1 and VDRs in cells of the immune system is part of an autocrine mechanism for defense against pathogens. One way such a mechanism acts is by promoting the secretion of antimicrobial peptides like β-defensin 2 (BD2) and cathelicidins26. For instance, the complex between 1,25(OH)D and VDR can bind with the promoter of the cathelicidin gene, expediting the transcription process and expanding the number of cathelicidins available for antimicrobial activities27, 28. This capability of the vitamin was proven in a previous study which found a superior level of cathelicidin expression in individuals with high serum 25-OHD levels29 and found to be emulated in lung epithelial cells30.

When released, cathelicidins can either directly extinguish pathogens of sundry sorts or neutralize the toxins, thus performing an immeasurably vital task in innate immunity31. In viral infections, the antimicrobial peptide is efficacious at combating viruses and curtailing their replications32, 33, 34, 35. This particular ability is also seen with BD-2, which could also stimulate the secretion and action of cytokines and chemokines responsible for the recruitment of immune cells to the site of infection36, 37, 38, 39. Together, BD-2 and cathelicidins are potent tools of the body to thwart pathogens and preclude the dilapidation of illness.

Interestingly, the expression of both the CYP27B1 enzyme and VDRs, or more obliquely the amount of 1,25(OH)D endogenously synthesized by immune cells, is influenced by the availability of pathogens, or more accurately, the abundance of Pattern Recognition Receptors (PRRs) that bind with them40, 41. Such an arrangement enables the immune cells to ratchet up their secretion of antimicrobial peptides upon detection of the pathogens they are meant to eliminate. However, it is not the only Vitamin D-related innate defense mechanism the human body employs when menaced by viruses.

One of the most rudimentary apparatuses in the body’s defense against any pathogen is barriers, which are principally upheld by cellular junctions—especially those of the epithelia—where Vitamin D wields excellent relevance. The 1,25(OH)D/VDR complex is capable of activating multiple signaling pathways responsible for the regulation of junction proteins and conferring structural integrity and functionality (such as in transport) to tissues42. To elaborate, VDRs have been shown to bind with the promoter sequence for the genes of proteins in the Claudin family which are essential to tight junctions and regulate their production43, 44, 45. There have also been indications that they are involved in regulating Occludin and ZO-1 proteins, which are integral to the junctions46, 47. For SARS-CoV-2, a virus that targets the respiratory system, it could be positively impacted by the modus operandi of Vitamin D, which has been shown to minimize lung permeability, strengthen pulmonary epithelial barriers against pathogenic invaders, and reduce the vulnerability to respiratory diseases48, 49.

Additionally, Vitamin D can also induce the procedures of autophagy, which is undertaken in cells infected with the pathogen and in cancerous cells50. This could be done through the upregulation of Beclin1, which can account for autophagy upon binding with class III phosphatidylinositol 3-kinase, or the downregulation of mammalian target of rapamycin (mTOR), which acts at various steps of the autophagy pathway to inhibit the process of cellular self-devouring51. As autophagy proceeds in a virus-borne cell, viral particles are bound for lysosomal degradation and antigen presentation, which would kickstart the type I Interferon (INF) antiviral pathway, thereby repressing viral replication and pathogenesis52, 53. The entirety of these factors above contributes to achieving the purpose of subjugating viral invaders in the human body.

Vitamin D’s Immunomodulatory Role Against Cytokine Storm

While the SARS-CoV-2 virus itself can adversely affect the afflicted body in various ways, perhaps more concerning and threatening are the body’s own mechanisms in tackling it. Importantly, an extravagance in inflammatory responses embodied by the “cytokine storm” has been associated with the severity of COVID-19 and its associated mortality54, 55, 56, 57. It has also been reported as a chief cause of fatality for the Middle East Respiratory Syndrome (MERS), the early 2000s Severe Acute Respiratory Syndrome (SARS), and influenza, in general58.

Conventionally, a cytokine storm, or even a proportionate release of cytokines, starts with antigen presentation, which leads to the activation of cells in both the immunological domain and the surrounding tissues. This triggers the secretion of such pro-inflammatory signal molecules as Interleukin 1 (IL-1), Interleukin 6 (IL-6), Interleukin 8 (IL-8), Interleukin 10 (IL-10), Interferon Gamma (IFNγ), and Tumor Necrosis Factor Alpha (TNF-α)59. The secretions of these molecules proceed in a positive feedback loop60, and the higher their serum levels are, the more lung inflammation and damage they are accountable for61, 62. This can be explicated as the cytokines attract and activate immune cells like macrophages and neutrophils, which are then prompted to release leukotrienes and reactive oxygen species (ROS) in an attempt to destroy pathogens that unfortunately entail collateral damage upon surrounding tissues63. In the case of SARS-CoV-2 in the respiratory tract, such tissues are those of the alveoli and the encompassing capillaries, the destruction of which could result in acute lung injury (ALI) or, worse, the deadly acute respiratory distress syndrome (ARDS)64, 65. Moreover, activated neutrophils can also deploy their intracellular genetic material to set up neutrophil extracellular traps (NETs) designed to ensnare pathogenic intruders in an exorbitant amount in the occurrence of a cytokine storm, leading to the occlusion of blood vessels called “immunothrombosis”66.

The entirety of this constitutes the pathogenesis of COVID-19 and presents a distinct case as to the disease’s lethal quality. Intriguingly, it is also subject to the influence of Vitamin D, whose manifold functions include being an immunomodulator, among other functions7.

Understanding the immunomodulatory role of steroidal vitamin, one can experience insight into adaptive immunity and the inflammatory pathway. Typically, adaptive immunological processes pertaining to this context begin with antigen presentation by APCs to naïve helper T cells, a process that activates them via the interaction between a T-cell receptor (TCR), a CD4 glycoprotein, and an antigen-MHC II complex (Class II Major Histocompatibility Complex)67. Activated helpers T cells can then differentiate into either type I helper T cells (Th1), majorly involving Interleukin 12 (IL-12)68, or type II helper T cells (Th2), notedly with the signaling of Interleukin 4 (IL-4)69, which promote cellular and humoral immune responses, respectively. For the former, IFNγ is secreted to promote inflammatory responses that incorporate the release of pro-inflammatory cytokines, whereas, for the latter, IL-4 and Interleukin 5 (IL-5) are secreted to activate antibody production by B lymphocytes70, 71, 72, 73. A homeostatic mechanism has been found to exist between the two; a comparative increase in the Th1 pathway can suppress the Th2 pathway, and vice versa74, 75.

As previously mentioned, the cytokine storm, an excessive release of pro-inflammatory cytokines, is harmful and often contributes to deterioration and death. Therefore, one would surmise that a disproportionate Th1 inflammatory response and an accompanying skewness in the Th1/Th2 ratio could potentially entail a lethal or, at least, devastating cytokine storm54, 76; this is where Vitamin D’s immunomodulatory role becomes highly relevant.

According to research data, 1,25(OH)D promotes the differentiation of naïve T cells into Th1 cells via increases in the amounts of GATA-3 and STAT6, which are transcription factors integral to the differentiation pathway77. Furthermore, the active steroid also inhibits IFNγ release while increasing IL-4 secretion78. Both of these effects contribute to the shift in the direction of T cells differentiation towards Th2, decreasing the amount of both Th1 cells and the potentially problematic pro-inflammatory cytokines they produce79. Moreover, 1,25(OH)D can also induce the differentiation of naïve T cells into regulatory T cells (Treg) responsible for the restraint of Th1 cells either by upregulating Foxp3, a crucial protein in the differentiation process or by manipulating with a cluster of differentiation (CD) molecules on the surface of dendritic cells, one of whose functions is to foster the development of Tregs80, 81. The totality of this helps to modulate the inflammatory pathway and safeguard the body against disease pathologies82.

Vitamin D and the Renin-Angiotensin Axis

One of the most critical reasons why the Renin-Angiotensin System (RAS) bears so much relevance in the topic of vitamin D is that COVID-19 pivots around the SARS-CoV-2’s infection mechanism.

Typically, the RAS acts to maintain the homeostasis of blood pressure, as well as blood electrolytes83. Its ultimate and most bioactive effector, the octapeptide Angiotensin II (Ang-II), usually binds with type I angiotensin receptors (AT1Rs) to attain the goal of increasing BP through vasoconstriction and the secretion of Aldosterone (which stimulates renal Na absorption and thus more water retention). However, the binding can also have adverse effects as it promotes inflammation, platelet aggregation, production of mitotic agents, and ROS synthesis (which diminishes the availability of nitric oxide, upon which the functionality of endothelial cells is dependent)84. These effects can morph into deleterious conditions, such as thrombosis, fibrosis, oxidative stress, and endothelial dysfunction84, 85.

Alternatively, Ang-II can also interact with Angiotensin-converting Enzyme 2 (ACE2), which cleaves away the phenylalanine at its carboxy terminus, turning it into Angiotensin–(1-7), which can also be produced from the sequential cleavages of Ang-II’s precursor, the decapeptide Angiotensin I (Ang-I), by Angiotensin-converting Enzyme (ACE) and ACE2, respectively83. Angiotensin-(1-7) then binds with the G protein-coupled receptor (GPCR) Mas, leading to effects opposite to those stemming from the interaction between Ang-II and AT1R—vasodilation, anti-fibrosis, anti-inflammation, and vascular protection, just to name a few86.

Unfortunately, SARS-CoV-2’s mechanism of entry into human cells happens to hinge upon ACE2. After the human serine-protease TMPRSS2 enzyme primes its spike proteins, they bind with ACE2 on the human cell membrane, beginning entry by receptor-mediated endocytosis87. As the virus proliferates, the binding of ACE2 becomes more extensive, and the availability of ACE2 plunges in the short term, ensured by the enzyme’s downregulation in the long term, decreasing Ang-II's conversion into Angiotensin-(1-7)88. This shifts the balance of the RAS greatly in that less binding between Angiotensin-(1-7) and Mas would be incurred, whereas the binding between Ang-II and AT1R would be elevated89. These interactions prove to be of great detriment for COVID-19 patients. The former has been described to protect the body against pulmonary fibrosis, acute lung injury, and fibrosis90, 91. The latter is where Vitamin D has profound effects upon alleviating the consequences of SARS-CoV-2 infection.

The steroidal hormone has been indicated to increase the expression of ACE2 and ergo, the activity of the ACE2/Angiotensin-(1-7)/Mas axis92, 93. This consequently suppresses the potentially pernicious ACE/Ang-II/AT1R axis and moderates the body’s inflammatory response, palliating acute lung injury and precluding multiple organ damage that could be precipitated by COVID-1994, 95.

Vitamin D Supplementation Against COVID-19?

While the aforementioned association between Vitamin D deficiency and either risk of COVID-19 contraction or severe outcomes, corroborated by all the germane mechanisms detailed above, might tantalize one to believe that Vitamin D supplementation can translate into protection against SARS-CoV-2, the reality is yet too complex for such a straightforward notion.

However, data from some research studies seem to substantiate the notion. For example, a meta-analysis96 found lower intensive care unit (ICU) admissions in COVID-19 patients supplemented with Vitamin D. One study97 also observed a decrease in disease severity, mortality rate, and serum level of markers of inflammation in Vitamin D-supplemented patients. Moreover, another study98 reported that high-dose Vitamin D supplementation aided the body’s clearance of SARS-CoV-2 and helped mildly symptomatic and asymptomatic individuals infected with COVID-19 to become COVID-19-negative. These findings are in line with that of a preceding study99 which reported that Vitamin D supplementation helped protect against acute respiratory infections.

Nevertheless, the current evidence is insufficient to conclude that Vitamin D supplements are substantively helpful against COVID-19 or for suggesting Vitamin D supplementation as a hedge against the disease. Furthermore, some studies would digress from such a conclusion. One100, for instance, found no significant difference in the length of hospitalization between patients given Vitamin D supplements and those given placebo. Another study101, albeit not precisely concerning COVID-19, also reported no reduction in pneumonia risk and an even elevated risk of pneumonia recurrence from taking oral Vitamin D supplements. Due to this reason, there remains more investigations to be executed and queries to be answered.

Conclusions

Multiple clinical studies and circumstantial observations have correlated Vitamin D levels and COVID-19 infection, severity, and mortality. This correlation could be rationalized by an insight into the multi-faceted roles of Vitamin D in the physiology of the human immune and endocrine systems.

On the immunological side, the steroidal hormone’s active form, 1,25(OH)D, can promote the secretion of antimicrobial peptides like Cathelicidins and BD-2, responsible for thwarting viral replication and achieving viral clearance. Vitamin D can also stimulate autophagy by upregulating Beclin1 and downregulating mTOR, leading to antigen presentation and subsequent activation of the type I INF antiviral pathway. It can also maintain cellular junctions, especially those in the respiratory epithelia, via regulation of Claudins, Occludin, and ZO-1, among a host of junction proteins, thus preserving the integrity of the body’s barriers and reducing their permeability against pathogens. Moreover, it is responsible for fostering naïve T cells into Th2 cells functioning in humoral immunity and inhibiting the inflammatory Th1 pathway, an immunomodulatory role that helps avert the calamitous cytokine storm. Meanwhile, on the endocrinological side, the vitamin can promote the activity of ACE2 and, thus, the binding between Angiotensin-(1-7) and Mas receptors, repressing that between Ang-II and AT1R could result in fibrosis and acute lung injury.

This whole prospective may appear promising and generate an incentive for Vitamin D supplementation as a protective measure against COVID-19. Yet, the current information pool is inadequate for one to suggest such a supplementation regimen. There remains a great deal of unclarity, and hence, a considerable necessity for even more thorough research in the future.

Abbreviations

1,25(OH)2D: 1,25-dihydroxyvitamin D

25-OHD: 25-hydroxyvitamin D

ACE2: Angiotensin-converting Enzyme 2

ACE: Angiotensin-converting Enzyme

ALI: Acute Lung Injury

Ang-II: Angiotensin II

APC: Antigen-presenting Cell

ARDS: Acute Respiratory Distress Syndrome

AT1R: Type I Angiotensin Receptor

BD-2: β-defensin 2

CD: Cluster of Differentiation

COVID-19: Coronavirus Disease 2019

CYP27B1: 1α-hydroxylase

GPCR: G protein-coupled receptor

IL-1: Interleukin 1

IL-4: Interleukin 4

IL-5: Interleukin 5

IL-6: Interleukin 6

IL-8: Interleukin 8

IL-10: Interleukin 10

IL-12: Interleukin 12

INF: Interferon

INF-γ: Interferon Gamma

MERS: Middle East Respiratory Syndrome

MHC II: Class II Major Histocompatibility Complex

mTOR: mammalian target of Rapamycin

NET: Neutrophil Extracellular Trap

PRR: Pattern Recognition Receptor

PTH: Parathyroid Hormone

RAS: Renin-Angiotensin System

ROS: Reactive Oxygen Species

SARS: Severe Acute Respiratory Syndrome

SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2

TCR: T-cell Receptor

Th1: Type I Helper T cells

Th2: Type II Helper T cells

TNF-α: Tumor Necrosis Factor Alpha

Treg: Regulatory T cells

VDR: Vitamin D Receptor

Acknowledgments

None

Author’s contributions

Not applicable.

Funding

None

Availability of data and materials

Not applicable

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

The author declares that he/she has no competing interests.

References

  1. B. Hu, H. Guo, P. Zhou, Z.L. Shi. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021; 19(3): 141-54.
  2. N. Ali. Role of vitamin D in preventing of COVID-19 infection, progression and severity. J Infect Public Health 2020; 13(10): 1373-80.
  3. C. Aranow. Vitamin D and the immune system. J Investig Med 2011; 59(6): 881-6.
  4. B. Prietl, G. Treiber, T.R. Pieber, K. Amrein. Vitamin D and immune function. Nutrients 2013; 5(7): 2502-21.
  5. G. Bivona, L. Agnello, M. Ciaccio. The immunological implication of the new vitamin D metabolism. Cent Eur J Immunol 2018; 43(3): 331-4.
  6. P.J. Martens, C. Gysemans, A. Verstuyf, A.C. Mathieu. Vitamin D's Effect on Immune Function. Nutrients 2020; 12(5): 1248.
  7. J.R. Goldsmith. Vitamin D as an Immunomodulator: Risks with Deficiencies and Benefits of Supplementation. Healthcare (Basel) 2015; 3(2): 219-32.
  8. D.A. Youssef, C.W. Miller, A.M. El-Abbassi, D.C. Cutchins, C. Cutchins, W.B. Grant. Antimicrobial implications of vitamin D. Dermatoendocrinol 2011; 3(4): 220-9.
  9. C.F. Gunville, P.M. Mourani, A.A. Ginde. The role of vitamin D in prevention and treatment of infection. Inflamm Allergy Drug Targets 2013; 12(4): 239-45.
  10. W. Dankers, E.M. Colin, J.P. van Hamburg, E. Lubberts. Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential. Front Immunol 2017; 7: 697.
  11. M. Infante, C. Ricordi, J. Sanchez, M.J. Clare-Salzler, N. Padilla, V. Fuenmayor. Influence of Vitamin D on Islet Autoimmunity and Beta-Cell Function in Type 1 Diabetes. Nutrients 2019; 11(9): 2185.
  12. D.O. Meltzer, T.J. Best, H. Zhang, T. Vokes, V. Arora, J. Solway. Association of Vitamin D Deficiency and Treatment with COVID-19 Incidence. MedRxiv 2020; :
  13. B. McCall. Vitamin D Deficiency in COVID-19 Quadrupled Death Rate [Internet]. Medscape. Medscape; 2020 [cited 2021Apr29]. Available from: https://www.medscape.com/viewarticle/942497. :
  14. A. Ahmad, C. Heumann, R. Ali, T. Oliver. Vitamin D levels in 19 European Countries & COVID-19 Mortality over 10 months. 2021. :
  15. A. Daneshkhah, V. Agrawal, A. Eshein, H. Subramanian, H.K. Roy, V. Backman. The Possible Role of Vitamin D in Suppressing Cytokine Storm and Associated Mortality in COVID-19 Patients. 2020. :
  16. D. De Smet, K. De Smet, P. Herroelen, S. Gryspeerdt, G.A. Martens. Vitamin D deficiency as risk factor for severe COVID-19: a convergence of two pandemics. MedRxiv 2020; :
  17. P.C. Ilie, S. Stefanescu, L. Smith. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clin Exp Res 2020; 32(7): 1195-8.
  18. S. Hovsepian, M. Amini, A. Aminorroaya, P. Amini, B. Iraj. Prevalence of vitamin D deficiency among adult population of Isfahan City, Iran. J Health Popul Nutr 2011; 29(2): 149-55.
  19. S. Hansdottir, M.M. Monick, N. Lovan, L. Powers, A. Gerke, G.W. Hunninghake. Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-linked chemokines and cytokines in airway epithelium while maintaining the antiviral state. J Immunol 2010; 184(2): 965-74.
  20. A.A. Ginde, J.M. Mansbach, C.A. Camargo. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 2009; 169(4): 384-90.
  21. J.R. Sabetta, P. DePetrillo, R.J. Cipriani, J. Smardin, L.A. Burns, M.L. Landry. Serum 25-hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults. PLoS One 2010; 5(6): e11088.
  22. I. Laaksi, J.P. Ruohola, P. Tuohimaa, A. Auvinen, R. Haataja, H. Pihlajamäki. An association of serum vitamin D concentrations < 40 nmol/L with acute respiratory tract infection in young Finnish men. Am J Clin Nutr 2007; 86(3): 714-7.
  23. J.J. Cannell, R. Vieth, J.C. Umhau, M.F. Holick, W.B. Grant, S. Madronich. Epidemic influenza and vitamin D. Epidemiol Infect 2006; 134(6): 1129-40.
  24. L.M. Bodnar, M.A. Krohn, H.N. Simhan. Maternal vitamin D deficiency is associated with bacterial vaginosis in the first trimester of pregnancy. J Nutr 2009; 139(6): 1157-61.
  25. M. Rodríguez, B. Daniels, S. Gunawardene, G.K. Robbins. High frequency of vitamin D deficiency in ambulatory HIV-Positive patients. AIDS Res Hum Retroviruses 2009; 25(1): 9-14.
  26. T.T. Wang, F.P. Nestel, V. Bourdeau, Y. Nagai, Q. Wang, J. Liao. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004; 173(5): 2909-12.
  27. S. Yim, P. Dhawan, C. Ragunath, S. Christakos, G. Diamond. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D(3). J Cyst Fibros 2007; 6(6): 403-10.
  28. J.P. Bilezikian, D. Bikle, M. Hewison, M. Lazaretti-Castro, A.M. Formenti, A. Gupta. Mechanism in endocrinology: vitamin D and COVID-19. Eur J Endocrinol 2020; 183(5): 133-47.
  29. L.A. Armas. Vitamin D, infections and immune-mediated diseases. Int J Clin Rheumatol 2009; 4(1): 89-103.
  30. S. Hansdottir, M.M. Monick, S.L. Hinde, N. Lovan, D.C. Look, G.W. Hunninghake. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J Immunol 2008; 181(10): 7090-9.
  31. B. Ramanathan, E.G. Davis, C.R. Ross, F. Blecha. Cathelicidins: microbicidal activity, mechanisms of action, and roles in innate immunity. Microbes Infect 2002; 4(3): 361-72.
  32. S. Tripathi, T. Tecle, A. Verma, E. Crouch, M. White, K.L. Hartshorn. The human cathelicidin LL-37 inhibits influenza A viruses through a mechanism distinct from that of surfactant protein D or defensins. J Gen Virol 2013; 94(Pt 1): 40-9.
  33. F.H. Sousa, V. Casanova, F. Findlay, C. Stevens, P. Svoboda, J. Pohl. Cathelicidins display conserved direct antiviral activity towards rhinovirus. Peptides 2017; 95: 76-83.
  34. P.G. Barlow, P. Svoboda, A. Mackellar, A.A. Nash, I.A. York, J. Pohl. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One 2011; 6(10): e25333.
  35. P.G. Barlow, E.G. Findlay, S.M. Currie, D.J. Davidson. Antiviral potential of cathelicidins. Future Microbiol 2014; 9(1): 55-73.
  36. M.E. Selsted, A.J. Ouellette. Mammalian defensins in the antimicrobial immune response. Nat Immunol 2005; 6(6): 551-7.
  37. T. Ganz. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003; 3(9): 710-20.
  38. L. Hazlett, M. Wu. Defensins in innate immunity. Cell Tissue Res 2011; 343(1): 175-88.
  39. J. Kim, Y.L. Yang, S.H. Jang, Y.S. Jang. Human β-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity. Virol J 2018; 15(1): 124.
  40. P.T. Liu, S. Stenger, H. Li, L. Wenzel, B.H. Tan, S.R. Krutzik. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311(5768): 1770-3.
  41. J.S. Adams, B. Rafison, S. Witzel, R.E. Reyes, A. Shieh, R. Chun. Regulation of the extrarenal CYP27B1-hydroxylase. J Steroid Biochem Mol Biol 2014; 144: 22-7.
  42. Zhang Y-guo. Wu S, Sun J. Vitamin D, vitamin D receptor and tissue barriers. Tissue Barriers 2013; 1(1):
  43. Y.G. Zhang, S. Wu, R. Lu, D. Zhou, J. Zhou, G. Carmeliet. Tight junction CLDN2 gene is a direct target of the vitamin D receptor. Sci Rep 2015; 5(1): 10642.
  44. M. Stio, L. Retico, V. Annese, A.G. Bonanomi. Vitamin D regulates the tight-junction protein expression in active ulcerative colitis. Scand J Gastroenterol 2016; 51(10): 1193-9.
  45. H. Fujita, K. Sugimoto, S. Inatomi, T. Maeda, M. Osanai, Y. Uchiyama. Tight junction proteins claudin-2 and -12 are critical for vitamin D-dependent Ca2+ absorption between enterocytes. Mol Biol Cell 2008; 19(5): 1912-21.
  46. R.A. Elizondo, Z. Yin, X. Lu, M.A. Watsky. Effect of vitamin D receptor knockout on cornea epithelium wound healing and tight junctions. Invest Ophthalmol Vis Sci 2014; 55(8): 5245-51.
  47. J. Kong, Z. Zhang, M.W. Musch, G. Ning, J. Sun, J. Hart. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol 2008; 294(1): 208-16.
  48. H. Chen, R. Lu, Y.G. Zhang, J. Sun. Vitamin D Receptor Deletion Leads to the Destruction of Tight and Adherens Junctions in Lungs. Tissue Barriers 2018; 6(4): 1-13.
  49. Y.Y. Shi, T.J. Liu, J.H. Fu, W. Xu, L.L. Wu, A.N. Hou. Vitamin D/VDR signaling attenuates lipopolysaccharide induced acute lung injury by maintaining the integrity of the pulmonary epithelial barrier. Mol Med Rep 2016; 13(2): 1186-94.
  50. M.A. Abdel-Mohsen, A.A. El-Braky, A.A. Ghazal, M.M. Shamseya. Autophagy, apoptosis, vitamin D, and vitamin D receptor in hepatocellular carcinoma associated with hepatitis C virus. Medicine (Baltimore) 2018; 97(12): e0172.
  51. J. Wang, H. Lian, Y. Zhao, M.A. Kauss, S. Spindel. Vitamin D3 induces autophagy of human myeloid leukemia cells. J Biol Chem 2008; 283(37): 25596-605.
  52. Y. Choi, J.W. Bowman, J.U. Jung. Autophagy during viral infection - a double-edged sword. Nat Rev Microbiol 2018; 16(6): 341-54.
  53. J. Mao, E. Lin, L. He, J. Yu, P. Tan, Y. Zhou. Autophagy and viral infection. Adv Exp Med Biol 2019; 1209: 55-78.
  54. D.C. Fajgenbaum, C.H. June. Cytokine Storm. N Engl J Med 2020; 383(23): 2255-73.
  55. S. Hojyo, M. Uchida, K. Tanaka, R. Hasebe, Y. Tanaka, M. Murakami. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen 2020; 40(1): 37.
  56. J.B. Moore, C.H. June. Cytokine release syndrome in severe COVID-19. Science 2020; 368(6490): 473-4.
  57. R.Q. Cron. COVID-19 cytokine storm: targeting the appropriate cytokine. Lancet Rheumatol 2021; 3(4): e236-7.
  58. R. Channappanavar, S. Perlman. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 2017; 39(5): 529-39.
  59. L. Tang, Z. Yin, Y. Hu, H. Mei. Controlling Cytokine Storm Is Vital in COVID-19. Front Immunol 2020; 11: 570993.
  60. A. Shimabukuro-Vornhagen, P. Gödel, M. Subklewe, H.J. Stemmler, H.A. Schlö\sser, M. Schlaak. Cytokine release syndrome. J Immunother Cancer 2018; 6(1): 56.
  61. C.K. Wong, C.W. Lam, A.K. Wu, W.K. Ip, N.L. Lee, I.H. Chan. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004; 136(1): 95-103.
  62. Y. Zhang, J. Li, Y. Zhan, L. Wu, X. Yu, W. Zhang. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun 2004; 72(8): 4410-5.
  63. J.M. Zhang, J. An. Cytokines, inflammation, and pain. Int Anesthesiol Clin 2007; 45(2): 27-37.
  64. S.A. Vardhana, J.D. Wolchok. The many faces of the anti-COVID immune response. J Exp Med 2020; 217(6): e20200678.
  65. G.H. Meftahi, Z. Jangravi, H. Sahraei, Z. Bahari. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of inflame-aging. Inflamm Res 2020; 69(9): 825-39.
  66. A. Bonaventura, A. Vecchié, L. Dagna, K. Martinod, D.L. Dixon, B.W. Van Tassell. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol 2021; 21(5): 319-29.
  67. R.V. Luckheeram, R. Zhou, A.D. Verma, B. Xia. CD4+ T cells: differentiation and functions. Clin Dev Immunol 2012; 2012: 925135.
  68. G. Trinchieri, S. Pflanz, R.A. Kastelein. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003; 19(5): 641-4.
  69. L. Chen, K.A. Grabowski, J.P. Xin, J. Coleman, Z. Huang, B. Espiritu. IL-4 induces differentiation and expansion of Th2 cytokine-producing eosinophils. J Immunol 2004; 172(4): 2059-66.
  70. W.E. Paul, R.A. Seder. Lymphocyte responses and cytokines. Cell 1994; 76(2): 241-51.
  71. A. Berger. Th1 and Th2 responses: what are they?. BMJ 2000; 321(7258): 424.
  72. T.R. Mosmann, R.L. Coffman. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7(1): 145-73.
  73. A.K. Abbas, K.M. Murphy, A. Sher. Functional diversity of helper T lymphocytes. Nature 1996; 383(6603): 787-93.
  74. Parris Kidd. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Alternative medicine review : a journal of clinical therapeutic 2003; 8(3): 223-46.
  75. W. van Eden, R. van der Zee, P. van Kooten, S.E. Berlo, P.M. Cobelens, A. Kavelaars. Balancing the immune system: Th1 and Th2. Annals of the Rheumatic Diseases 2002; 61(Supplement 2): 25-28.
  76. R. Silva, J.M. Morgado, A. Freitas, A. Couceiro, A. Orfao, F. Regateiro. Influence of pro- and anti-inflammatory cytokines in Th1 polarization after allogeneic stimulation. Int J Biomed Sci 2005; 1(1): 46-52.
  77. M.T. Cantorna, L. Snyder, Y.D. Lin, L. Yang. Vitamin D and 1,25(OH)2D regulation of T cells. Nutrients 2015; 7(4): 3011-21.
  78. G. Bivona, L. Agnello, M. Ciaccio. Vitamin D and Immunomodulation: Is It Time to Change the Reference Values?. Ann Clin Lab Sci 2017; 47(4): 508-10.
  79. S.W. Kang, S.H. Kim, N. Lee, W.W. Lee, K.A. Hwang, M.S. Shin. 1,25-Dihyroxyvitamin D3 promotes FOXP3 expression via binding to vitamin D response elements in its conserved noncoding sequence region. J Immunol 2012; 188(11): 5276-82.
  80. L. Adorini. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes. Ann N Y Acad Sci 2003; 987(1): 258-61.
  81. M.T. Cantorna, C. Munsick, C. Bemiss, B.D. Mahon. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000; 130(11): 2648-52.
  82. J.H. Fountain, S.L. Lappin. Physiology, Renin Angiotensin System. 2021; :
  83. P. Dandona, S. Dhindsa, H. Ghanim, A. Chaudhuri. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 2007; 21(1): 20-7.
  84. A.M. Murphy, A.L. Wong, M. Bezuhly. Modulation of angiotensin II signaling in the prevention of fibrosis. Fibrogenesis & Tissue Repair 2015; 8: 7.
  85. R.A. Santos, A.C. Simoes e Silva, C. Maric, D.M. Silva, R.P. Machado, I. de Buhr. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100(14): 8258-63.
  86. M. Hoffmann, H. Kleine-Weber, S. Schroeder, N. Krüger, T. Herrler, S. Erichsen. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; 181(2):
  87. F. Silhol, G. Sarlon, J.C. Deharo, B. Vaisse. Downregulation of ACE2 induces overstimulation of the renin-angiotensin system in COVID-19: should we block the renin-angiotensin system?. Hypertens Res 2020; 43(8): 854-6.
  88. M. Gheblawi, K. Wang, A. Viveiros, Q. Nguyen, J.C. Zhong, A.J. Turner. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res 2020; 126(10): 1456-74.
  89. V. Bhalla, C.A. Blish, A.M. South. A historical perspective on ACE2 in the COVID-19 era. J Hum Hypertens 2020; :
  90. B.N. Zhang, H. Xu, X.M. Gao, G.Z. Zhang, X. Zhang, F. Yang. Protective Effect of Angiotensin (1-7) on Silicotic Fibrosis in Rats. Biomed Environ Sci 2019; 32(6): 419-26.
  91. A. Malek Mahdavi. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: implications for a potential treatment for COVID-19. Rev Med Virol 2020; 30(5): e2119.
  92. C.S. McLachlan. The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention and treatment of COVID-19 are distinctly different paradigms. Clin Hypertens 2020; 26(1): 14.
  93. J. Xu, J. Yang, J. Chen, Q. Luo, Q. Zhang, H. Zhang. Vitamin D alleviates lipopolysaccharide‑induced acute lung injury via regulation of the renin‑angiotensin system. Mol Med Rep 2017; 16(5): 7432-8.
  94. H. Aygun. Vitamin D can prevent COVID-19 infection-induced multiple organ damage. Naunyn Schmiedebergs Arch Pharmacol 2020; 393(7): 1157-60.
  95. K. Shah, D. Saxena, D. Mavalankar. Vitamin D supplementation, COVID-19 and disease severity: a meta-analysis. QJM: An International Journal of Medicine 2021; 114(3): 175-181.
  96. L. Nikniaz, M.A. Akbarzadeh, H. Hosseinifard, M.-S. Hosseini. The impact of vitamin D supplementation on mortality rate and clinical outcomes of COVID-19 patients: A systematic review and meta-analysis. MedRxiv 2021; :
  97. A. Rastogi, A. Bhansali, N. Khare, V. Suri, N. Yaddanapudi, N. Sachdeva. Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study). Postgrad Med J 2020; :
  98. A.R. Martineau, D.A. Jolliffe, R.L. Hooper, L. Greenberg, J.F. Aloia, P. Bergman. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 2017; 356: i6583.
  99. I.H. Murai, A.L. Fernandes, L.P. Sales, A.J. Pinto, K.F. Goessler, C.S. Duran. Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial. JAMA 2021; 325(11): 1053-60.
  100. S. Sloka, C. Silva, J. Wang, V.W. Yong. Predominance of Th2 polarization by vitamin D through a STAT6-dependent mechanism. J Neuroinflammation 2011; 8(1): 56.
  101. S. Manaseki-Holland, Z. Maroof, J. Bruce, M.Z. Mughal, M.I. Masher, Z.A. Bhutta. Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: a randomised controlled superiority trial. Lancet 2012; 379(9824): 1419-27.

Comments